drugset
drugset / Trial / NCT00628420

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

NCT00628420 ↗

Phase 1 Completed 45 enrolled University of Texas Southwestern Medical Center ACADIA Pharmaceuticals Inc. · collabStanley Medical Research Institute · collab
RandomizedParallel-groupDouble-blind

Summary

To determine the safety and tolerability of ACP-104 after oral administration of single doses in comparison with placebo to schizophrenia or other psychotic disorders.

Timeline

Start
2005-01
Primary completion
2006-11
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject N-desmethylclozapine Small molecule 25 mg Oral
Subject N-desmethylclozapine Small molecule 50 mg Oral
Subject N-desmethylclozapine Small molecule 75 mg Oral
Subject N-desmethylclozapine Small molecule 100 mg Oral
Subject N-desmethylclozapine Small molecule 125 mg Oral
Subject N-desmethylclozapine Small molecule 150 mg Oral
Subject N-desmethylclozapine Small molecule 175 mg Oral
Subject N-desmethylclozapine Small molecule 200 mg Oral
Subject N-desmethylclozapine Small molecule 225 mg Oral
Subject N-desmethylclozapine Small molecule 250 mg Oral
Subject N-desmethylclozapine Small molecule 275 mg Oral
Subject N-desmethylclozapine Small molecule 300 mg Oral

Indications

schizophrenia